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Background: Several studies have examined the links between hypertension, vascular damage, 
and cognitive impairment. The functions most commonly involved seem to be those associated 
with memory and executive function.
Aims: 1) to report the cognitive evolution in a cohort of hypertensive patients, 2) to identify the 
affected domains, and 3) to correlate the results obtained with blood pressure measurements.
Materials and Methods: Observational 6-year follow-up cohort study including both males 
and females aged $65 and #80 years, and hypertensive patients under treatment. Patients with 
a history of any of the following conditions were excluded: stroke, transient ischemic attack, 
diabetes mellitus, atrial fibrillation, cardiac surgery, dementia, or depression. Four neurocognitive 
evaluations were performed (at baseline and every 2 years). The tests used evaluated memory 
and executive function domain. Blood pressure was measured on every cognitive evaluation.
Results: Sixty patients were followed for 76.4 ± 2.8 months. The average age at baseline was 
72.5 ± 4.2 and 77.9 ± 4.6 at 6 years (65% were women). Two patients were lost to follow up 
(3.3%) and 8 patients died (13.3%).The density incidence for dementia was 0.6% patients per 
year (pt/y) (n = 3) and for depression was 1.6% pt/y (n = 12). No changes were observed in 
either memory impairment or the Mini Mental State Examination (MMSE) results (p = ns) 
during follow-up. A progressive impairment of the executive function was shown regardless of 
the blood pressure measurements.
Conclusion: 1) the incidence of dementia doubled to general population, 2) the initial memory 
impairment did not change during the evaluation period, 3) cognitive impairment worsened in 
the areas related to executive function (prefrontal cortex) regardless of the adequacy of anti-
hypertensive treatment and blood pressure values.
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Introduction
We have already described the difference between cognitive “impairment”, and the 
cognitive “decline” typically observed during aging, and concluded that in hyperten-
sive patients the most commonly involved cognitive domains were long-term memory 
and executive functioning.1 There is clear evidence that hypertension produces many 
pathological changes in the vascular system. Because it affects the brain, hypertension 
is the most important risk factor for stroke.2 Apart from this complication, however, 
high blood pressure may damage the brain blood vessels, cause white matter lesions, 
and lead to both cortical and subcortical volume loss. These conditions may cause 
cognitive impairment, vascular dementia and, in some cases, even contribute to the 
progression of Alzheimer´s disease. Due to the long-term subclinical nature of these Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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conditions, it is essential to use neuropsychological tests to 
study them.3,4 The increasing interest in the prevention, early 
detection, and management of cognitive impairment is the 
foundations of our investigation. The aims of this study were 
to observe the cognitive evolution, initially impaired, in our 
sample of hypertensive patients for 6 years, and to correlate 
our results with the blood pressure values (achieved thera-
peutic goals) and anti-hypertensive medications used.
Materials and methods
During the recruitment phase for 5 months, between 
December 2001 and April 2002, all patients seen in the 
outpatient cardiology clinic of the Hospital Español in 
Buenos Aires, Argentina, were invited to participate in the 
trial if they met the inclusion criteria. Both male and female 
patients $65 years of age with a hypertension diagnosis 
were included in this study. Individuals with a history of 
neurologic disease (stroke, transitory ischemic attack), 
psychiatric disease (depression or dementia according to 
the Diagnostic and   Statistical Manual of Mental Disorders 
(DSM-IV),5   m e tabolic disease, diabetes mellitus (accord-
ing to the standard of the American Diabetes Association),6 
dislipemia (defined as the use of cholesterol-lowering drugs, 
low-density lipoprotein .160 mg/dL, or nonhigh-density 
lipoprotein .190 mg/dL), and cardiovascular disease (heart 
failure, atrial fibrillation and cardiac surgery), as well as those 
on cholinesterase inhibitors, glutamatergic or antipsychotic 
inhibitors, were excluded. Sixty caucasian patients out of 520 
consecutive patients signed an informed consent to partici-
pate in a 6-year follow-up trial.   Hypertension was defined as 
systolic blood pressure (SBP) $140 mm Hg and/or diastolic 
blood pressure (DBP) $90 mm Hg at office visit and/or on 
three occasions throughout their clinical history or if they 
were taking specific antihypertensive   medication. Blood 
pressure (BP) was measured according to both national and 
international guidelines,7,8 together with each cognitive evalu-
ation. The anti-hypertensive medication was not modified 
during follow-up. Other clinical conditions (cardiac diseases, 
cerebral diseases, etc) were recorded. In the benzodiazepine-
treated group, benzodiazepine was discontinued 72 hours 
before each cognitive evaluation. The trial was approved by 
an Independent Ethics Committee (IEC), pursuant to inter-
national Good Clinical Practice (GCP), the local regulations, 
and the Declaration of Helsinki and its amendments.
The neuropsychological assessment battery used in our 
Center included the following test: a) Folstein’s Mini Mental 
Statement Examination (MMSE)9 cut-off point 24,10 b) New 
York University (NYU) Paragraph Test to evaluate both short 
and long-term memory,11 c) Trial Making Test12 parts A and 
B (TMT A and B), d) the clock drawing test,13 e) Stroop Test 
(Colors and Words),14 and g) before each assessment patients 
answered a “Hospital Anxiety-Depression Scale” (HAD) 
questionnaire to evaluate whether the anxiety and/or depres-
sion – two conditions that alter the cognitive results – were 
present.15 These tests were administered by neuropsycholo-
gists at the beginning of the study and then every 2 years.
Study design and statistics
This is an observational, cohort, 6-year follow up study. The 
SPSS 17.0 statistic package was used. While the categorical 
variables are expressed in percentages, the continuous vari-
ables are expressed with mean ± standard deviation (SD). 
For paired samples, the t-test was used. For analysis of vari-
ance, ANOVA was used, either parametric or nonparametric 
Kruskall–Wallis when the distribution was not gaussian or 
the test used points. The statistical tests were performed for 
a significance level ,0.05.
Results
The general baseline characteristics of the group, blood pres-
sure, schooling, age (72.5 ± 4.2 years) and the proportion of 
patients by gender (women 56.6% vs 65%), were included 
in Table 1. After 6 years of follow-up, the average age of 
the hypertensive patients was 77.9 ± 4.6 years. At the time 
of enrollment 28.3% of the hypertensive patients were not 
Table 1 general characteristics of the hypertensive patients
Variable Hypertensive patients (n = 60)
n %
Age (y)1 72.5 ± 4.2
Female 39 65
schooling level
  grammar school 35 58.3
  High-school 20 33.3
  college studies 5 8.3
Blood pressure (BP)2
systolic BP 141.4 ± 17.8
80.8 ± 9.02
60.5 ± 16.6
Diastolic BP 
Pulse pressure 
Obesity3 10 16.6
smoking
  nonsmokers4 50 83.3
  smokers 10 16.6
cardiopathy
  coronary pathology 7 11.6
  Arrhythmia5 12 20
Psychotropics use6 27 45
Notes: Age: years, x ± De;1 BP: mm Hg;2 obesity: body mass index $30 kg/m;2,3 
smoking: had never smoked or had not smoked for more than a year;4 arrhythmia: 
extrasystoles supra and/or ventricular;5 psychotropics: benzodiazepines.6Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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controlled and hypertension had been present for 10.2 ± 8.2 
(range, 5–30) years. The evolution of the cognitive domains 
studied (average ± SD) after 76.4 ± 2.8 months of follow-up 
is shown in Table 2. During follow-up, 2 patients were lost 
to follow up (3.3%) and 8 patients died (13.3%) (Table 3). 
Three patients developed dementia (density incidence 0.6% 
pt/y) and were excluded from the following neuropsycho-
logical tests. The depression density incidence was 1.6% pt/y 
(n = 12). Patients with depression were treated and none had 
clinical signs at the time of evaluation. Memory impair-
ment both in the short and long term remained unchanged 
during follow-up (baseline short-term memory 4 ± 2.1 vs 
final short-term memory 5 ± 2.4, pt = ns; basal long-term 
memory 6 ± 2.5 vs final long-term memory 6 ± 2.8, pt = ns). 
Throughout follow-up the results of the MMSE were nor-
mal (baseline 28 ± 1.6 vs final points 29 ± 2.2, pt = ns). 
A more marked impairment was observed in tests evaluating 
executive   function. Performance in the Stroop test decreased 
throughout the follow-up showing more interference (basal 
results −0.6 ± 5.8 vs final results −2.3 ± 8.6, P = 0.031) 
 ( Figure 1). The capacity to perform TMT part B progressively 
decreased showing statistical significance at 4 years compared 
with the basal result (16.6% [n = 10] vs 38.2% (n = 18), 
pt = 0.033), whereas after 6 years the downward tendency was 
(16.6% [n = 10] vs 34% [n = 16], pt = 0.061) (Figure 2). The 
results of the cognitive tests showed no relationship with SBP 
or DBP values or pulse pressure (PP). The antihypertensive 
treatment was not modified by the investigators. When com-
pared the cognitive performance with the different classes of 
antihypertensive drugs, used in monotheraphy or combined 
therapy, no differences were shown.
Discussion
The relationship between the vascular damage caused by 
hypertension in brain structures, and the development of 
cognitive disorders and/or dementia several years later, has 
been widely investigated in epidemiological longitudinal 
studies.16–23 However, not all cognitive domains are equally 
affected by hypertension. In previous observations we 
showed that the executive functions related to the prefrontal 
cortex in hypertensive patients were more affected than those 
of patients with normal blood pressure.1
The vulnerability to hypoxia and cerebral hypoperfusion 
is not homogenous in all regions of the brain.24 The frontal 
lobes – particularly the prefrontal cortex – are more vulner-
able to aging and even more to the effects of hypertension 
because of their phylogenetically younger structures.25
A study of frontal function in hypertensive nonhuman pri-
mates (rhesus Macaque mulatta monkeys) concluded that in 
this model of cerebral vascular damage, the abstraction capacity 
and the executive function were both altered compared with 
frontal function in nonhypertensive monkeys.26 Sabatini et al 
observed that anti-hypertensive treatment with different cal-
cium antagonists increased the cellularity of all layers of the 
prefrontal cortex in spontaneously hypertensive rats (SHR).27
The frontal lobes, representing 29% of the cortex and the 
most advanced functions of the brain, called executive func-
tions, depend on the integrity of this lobes.28 Three-way circuits 
connecting the frontal lobes with the subcortex structures and 
clinical behavioral syndromes depend on the damaged circuit.29 
In our study, the hypertensive patients showed a progressive 
impairment of executive function during the years studied, 
reflected by means of the TMT-B and the Stroop test.
The activity of the frontal lobes is strictly related to 
blood flow.30 These regional brain flow changes are clearly 
visible in hypertensive patients, which affects their cogni-
tive performance; it seems that, with the passing of time, 
the duration of hypertension contributes significantly to 
these changes.24,31 However, in the same way that the loss 
of secondary vasomotor capacity in hypertensive disorders 
leads to the redistribution of blood flow as a mechanism of 
adaptation, cognitive activities also use these mechanisms 
Table 2 cognitive evolution during the follow-up
Variable Basal (n = 60) 2 years (n = 51) 4 years (n = 47) 6 years (n = 47) P value
systolic BP (mm Hg) 140 ± 16.5 140 ± 17.3 146.5 ± 19.9 148 ± 21.4 ns
Diastolic BP (mm Hg) 80 ± 8.4 80 ± 8.6 80 ± 9.8 85 ± 8.9 ns
Pulse pressure 60 ± 15 60 ± 15.6 60 ± 16,8 64 ± 18.2 ns
MMse 28 ± 1.6 29 ± 1.0 29 ± 1.1 29 ± 2.2 ns
short-term memory 4 ± 2.1 5 ± 2.8 4 ± 2.2 5 ± 2.4 ns
Long-term memory 6 ± 2.5 8 ± 3.8 6 ± 3.0 6 ± 2.8 ns
TMT-B nonexecution 10 (16.6%) 12 (23.5%) 18 (38.2%)* 16 (34.0%) = 0.061
stroop test −0.6 ± 5.8 −0.9 ± 5.9 −1.2 ± 6.6  −2.3 ± 8.6 = 0.013
Note: *P = 0.033 vs baseline.
Abbreviations: BP, blood pressure; MMse, Mini Mental state examination; TMT-B, Trial Making Test part B.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
284
Vicario et al
in order to perform complex activities with limited blood 
flow. Likewise, cognitive deficits are difficult to detect using 
conventional tests and subclinical disorders occur within 
years. This may explain why the MMSE, a low sensitivity 
and low specificity though useful test, did not change during 
follow-up. Consequently we had to use specific tests able to 
detect failure in executive functions.
On the other hand, the basal long-term memory impairment 
did not show a negative evolution during follow-up, despite 
being one of the first cognitive domains involved and it is the 
most common chief complaint in this type of patients.32
A possible hypothesis for these associations in hyper-
tensive patients is probably due to the direct consequences 
of the demyelinization (caused by hypoxia and consecu-
tive ischemia),23 and may cause the “disconnection” of 
  subcortical–cortical loops.33,34 This lack of communication 
between the dorsolateral prefrontal cortex and the nuclei of 
the base by means of the caudate nucleus may be responsible 
for the “executive dysfunction”.
Depression is a common and under diagnosed symptom in 
elderly people, characterized mainly by cognitive symptoms 
(including slow thinking and volition-affected behaviour), 
which depend on the integrity of the frontal lobes and make 
the mind rigid.35 However, the density incidence for depres-
sion is within the expected range in patients .65 years old 
(1.6% pt/y),36 whereas the incidence density for dementia 
doubled compared with the general population (0.6% pt/y). 
Many of the cohorts studied have no selective screening for 
cardiovascular diseases that may appear as confounders or 
disparities related to the schooling. Our cohort though small 
has been carefully classified and followed for a reasonable 
time in order to observe cognitive changes.
Lastly, the blood pressure values during follow-up show 
a group of well-controlled patients, despite the fact that cog-
nitive impairment grew worse and, although the sample is 
small no differences were observed in cognitive tests when 
analyzing patients according to BP values divided into con-
trolled (#139 and/or #89 mmHg) and noncontrolled ($140 
and/or $90 mmHg). This result also shows the need to do 
systematic neuropsychological screening when hypertensive 
patients are clinically examined so as to detect a possibly very 
narrow “window space” to intervene and stop the progression 
of cognitive impairment. We did not notice any changes in 
length of time of the disease or class of anti-hypertensive 
drugs used.
For a long time now, frontal lobes were called silent lobes. 
It is beyond doubt that hypertension is a risk factor for cogni-
tive impairment, dementia, and/or depression. Both memory 
and executive functions seem to become impaired more 
often. The “dys-executive” syndrome (prefrontal domains) 
appears prematurely and its evolution seems to be progres-
sive compared with memory, which seems to be affected 
more slowly. The unfavorable cognitive evolution does not 
seem to be related to the BP values or the antihypertensive 
treatments.
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Figure 2 Trial Making Test part B change during follow-up (expressed as % of 
patients who did not perform the test).
Table 3 Mortality causes
Causes N % of total deaths
cardiac disease 50
  Heart failure 2
  Myocardial infarction 1
  sudden death 1
stroke 25
  cerebral aneurysm 1
  cerebral hemorrhage 1
Oncologic disease 25
  Leukemia 1
  endometrial cancer 1
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Figure 1 stroop test change during follow-up (expressed as a level of interference 
between colors and words).Vascular Health and Risk Management
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